Retroviral replicating vectors in cancer.

[1]  A. Melcher,et al.  Recent clinical experience with oncolytic viruses. , 2012, Current pharmaceutical biotechnology.

[2]  Harry E. Gruber,et al.  Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector , 2011, Neuro-oncology.

[3]  N. Rainov,et al.  Clinical development of experimental virus-mediated gene therapy for malignant glioma. , 2011, Anti-cancer agents in medicinal chemistry.

[4]  P. Zanovello,et al.  Immune response to Moloney-murine leukemia virus-induced antigens in bone marrow. , 2011, Immunology letters.

[5]  J. Nemunaitis,et al.  Clinical development directions in oncolytic viral therapy , 2011, Cancer Gene Therapy.

[6]  Clare Jolly,et al.  Cell-to-cell transmission of retroviruses: Innate immunity and interferon-induced restriction factors , 2011, Virology.

[7]  Brian Salmons,et al.  Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma , 2011, Journal of Neuro-Oncology.

[8]  S. Riddell,et al.  The emperor of all maladies: A biography of cancer , 2011 .

[9]  T. Cripe,et al.  Oncolytic virotherapy reaches adolescence , 2010, Pediatric blood & cancer.

[10]  Á. McKnight,et al.  A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5α independent , 2010, Retrovirology.

[11]  J. Hiscott,et al.  The interface between the innate interferon response and expression of host retroviral restriction factors. , 2010, Cytokine.

[12]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[13]  Takahiro Kimura,et al.  Optimization of enzyme–substrate pairing for bioluminescence imaging of gene transfer using Renilla and Gaussia luciferases , 2010, The journal of gene medicine.

[14]  Thomas C Chen,et al.  Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene , 2010, Cancer Gene Therapy.

[15]  Albert Koong,et al.  Impaired interferon signaling is a common immune defect in human cancer , 2009, Proceedings of the National Academy of Sciences.

[16]  P. Fisher,et al.  Searching for a cure: Gene therapy for glioblastoma , 2008, Cancer biology & therapy.

[17]  H. Takeuchi,et al.  Host factors involved in resistance to retroviral infection , 2008, Microbiology and immunology.

[18]  J. Huff.  The Secret History of the War on Cancer , 2008, Environmental Health Perspectives.

[19]  C. Cordon-Cardo,et al.  Highly Efficient Gene Delivery for Bladder Cancers by Intravesically Administered Replication-Competent Retroviral Vectors , 2007, Clinical Cancer Research.

[20]  N. Lemp,et al.  Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. , 2007, Journal of molecular biology.

[21]  C. Tai,et al.  Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. , 2007, Cancer research.

[22]  Brian Salmons,et al.  Effects of Viral Strain, Transgene Position, and Target Cell Type on Replication Kinetics, Genomic Stability, and Transgene Expression of Replication-Competent Murine Leukemia Virus-Based Vectors , 2007, Journal of Virology.

[23]  S. Russell,et al.  History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  J. Aragon-Ching,et al.  CNS Metastasis: An Old Problem in a New Guise , 2007, Clinical Cancer Research.

[25]  C. Cordon-Cardo,et al.  Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts , 2007, Cancer Gene Therapy.

[26]  Takahiro Kimura,et al.  Tumor-Selective Gene Expression in a Hepatic Metastasis Model after Locoregional Delivery of a Replication-Competent Retrovirus Vector , 2006, Clinical Cancer Research.

[27]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[28]  Brian Salmons,et al.  Tissue- and Tumor-Specific Targeting of Murine Leukemia Virus-Based Replication-Competent Retroviral Vectors , 2006, Journal of Virology.

[29]  A. Sonabend,et al.  Oncolytic adenoviral therapy for glioblastoma multiforme. , 2006, Neurosurgical focus.

[30]  D. Klatzmann,et al.  Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. , 2005, Current gene therapy.

[31]  Thomas C. Chen,et al.  Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Manish I. Patel,et al.  A Pitfall of the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) Assay due to Evaporation in wells on the Edge of a 96 well Plate , 2005, Biotechnology Letters.

[33]  Thomas C Chen,et al.  Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. , 2003, Human gene therapy.

[34]  R. Matusik,et al.  Tissue-Specific Transcriptional Targeting of a Replication-Competent Retroviral Vector , 2002, Journal of Virology.

[35]  Christina R. Miller,et al.  Inserting a Nuclear Targeting Signal into a Replication-Competent Moloney Murine Leukemia Virus Affects Viral Export and Is Not Sufficient for Cell Cycle-Independent Infection , 2002, Journal of Virology.

[36]  C. Springer,et al.  The emerging fields of suicide gene therapy and virotherapy. , 2002, Trends in molecular medicine.

[37]  F. McCormick,et al.  Cancer gene therapy: fringe or cutting edge? , 2001, Nature Reviews Cancer.

[38]  C. Tai,et al.  Genomic Stability of Murine Leukemia Viruses Containing Insertions at the Env-3′ Untranslated Region Boundary , 2001, Journal of Virology.

[39]  S. Hughes,et al.  Adaptation of Chimeric Retroviruses In Vitro and In Vivo: Isolation of Avian Retroviral Vectors with Extended Host Range , 2001, Journal of Virology.

[40]  W. Anderson,et al.  A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. , 2001, Human gene therapy.

[41]  B. Berkhout,et al.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Astrup.  Gene therapy of glioblastoma , 2001 .

[43]  A. Rehemtulla,et al.  Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. , 1999, Cancer research.

[44]  T. Friedmann.  The maturation of human gene therapy , 1996, Acta paediatrica.

[45]  S. Hughes,et al.  Gene transfer into mammalian cells by a Rous sarcoma virus-based retroviral vector with the host range of the amphotropic murine leukemia virus , 1996, Journal of virology.

[46]  L. Xiao,et al.  Effects of adoptive immune transfers on murine leukemia virus-infection of rats. , 1995, Virology.

[47]  M. Emerman,et al.  Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus , 1994, Journal of virology.

[48]  P. Brown,et al.  Integration of murine leukemia virus DNA depends on mitosis. , 1993, The EMBO journal.

[49]  J. Olson.  The History of Cancer: An Annotated Bibliography , 1989 .

[50]  R. Jaenisch,et al.  Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance , 1989, Molecular and cellular biology.

[51]  S. Goff,et al.  Construction and recovery of viable retroviral genomes carrying a bacterial suppressor transfer RNA gene. , 1985, Science.

[52]  R. Jaenisch,et al.  Replication-competent Moloney murine leukemia virus carrying a bacterial suppressor tRNA gene: selective cloning of proviral and flanking host sequences. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Kelloff,et al.  Naturally occurring humoral immunity to endogenous xenotropic and amphotropic type‐C virus in the mouse , 1981, International journal of cancer.

[54]  Thomas C. Chen,et al.  Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. , 2006, Neurosurgical focus.

[55]  N. Kasahara,et al.  Retrovirus-Mediated Gene Transfer to Tumors , 2004 .

[56]  N. Kasahara,et al.  Retrovirus-mediated gene transfer to tumors: utilizing the replicative power of viruses to achieve highly efficient tumor transduction in vivo. , 2004, Methods in molecular biology.

[57]  D. Klatzmann,et al.  Replicative retroviral vectors for cancer gene therapy , 2003, Cancer Gene Therapy.

[58]  B. Preston,et al.  Mechanisms of retroviral mutation. , 1996, Trends in microbiology.